Mr. Andre Larente reports

DIAGNOS ANNOUNCES VOTING RESULTS OF MEETING OF SHAREHOLDERS

Diagnos Inc. has released the voting results of the annual meeting of the shareholders held earlier today.

Andre Larente, Robert Dunn, Michael Braeuel and Philippe Couillard were elected as directors to hold office until the closing of the next annual meeting of the shareholders.

Grant Thornton LLP was appointed auditor of the corporation for the year ending March 31, 2026.

Diagnos also announces a grant of an aggregate number of 1.1 million stock options to two directors of the corporation in replacement for 600,000 stock options, which expired on Aug. 26, 2025, and 500,000 stock options expiring Sept. 28, 2025. The date of the grant is Sept. 25, 2025. The expiry date to which the stock options can be exercised is Sept. 25, 2030. Stock options vest at 50 per cent per year, commencing with the first anniversary of the grant. The exercise price of the stock options granted has been established at 26 cents per common share. The grant remains subject to regulatory compliance, including TSX Venture exchange acceptance.

Moneys quoted in this press release shall be stated in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.